A
Artiva Biotherapeutics, Inc. (ARTV)
NGM – Real vaqt narxi. Valyuta: USD
10.63
+0.03 (0.28%)
Yopilishda: May 12, 2026, 4:00 PM EDT
10.60
-0.03 (-0.28%)
Bozor oldidan: May 13, 2026, 6:15 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
10.63
+0.03 (0.28%)
Yopilishda: May 12, 2026, 4:00 PM EDT
10.60
-0.03 (-0.28%)
Bozor oldidan: May 13, 2026, 6:15 AM EDT
Artiva Biotherapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, autoimmun kasalliklar va saratondan aziyat chekayotgan bemorlar uchun tabiiy killer (NK) hujayralariga asoslangan terapiyalarni ishlab chiqishga qaratilgan. Uning yetakchi mahsulot nomzodi AlloNKni o'z ichiga oladi, bu autoimmun kasalliklar va saraton kasalliklari, jumladan revmatoid artrit, tizimli qizil yug'rich, buyrak qizil yug'richi, revmatoid artrit, pemfigus vulgaris, granulomatoz bilan polianjiit/mikroskopik polianjiitning anti-neyrofil sitoplazmatik antitelalar bilan bog'liq vaskulit kichik turlari va B-hujayrali-Xodgkin bo'lmagan limfoma uchun tayyor NK hujayra terapiyasi. Kompaniya, shuningdek, ko'krak bezi, oshqozon va qizilo'ngach, va siydik pufagi saratoni kabi turli xil qattiq o'smalarni davolash uchun allogenik anti-inson epidermal o'sish omil retseptor 2 (HER2) ga qarshi kimera antigen retseptor (CAR)-NK hujayra mahsuloti nomzodi AB-201ni ishlab chiqadi; va gematologik malignansiyalarni davolash uchun allogenik anti-CD5 CAR-NK hujayra mahsuloti nomzodi AB-205ni ishlab chiqadi. Artiva Biotherapeutics, Inc. 2019-yilda ro'yxatga olingan va bosh qarorgohi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations |
| Dr. Fred Aslan M.D. | President, CEO & Director |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development |
| Dr. Nicholas Veomett Ph.D. | Vice President of Corporate Development |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor |
| Mr. Andrew Cronauer | VP, General Counsel & Corporate Secretary |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs |
| Mr. Christopher P. Horan | Chief Technical Operations Officer |
| Mr. Thad Huston C.M.A. | CFO and Principal Financial & Accounting Officer |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 10-Q | artv-20260331.htm |
| 2026-04-30 | 10-K/A | artv-20251231.htm |
| 2026-03-10 | S-8 | artv-20260310.htm |
| 2026-03-10 | 8-K | artv-20260310.htm |
| 2026-02-24 | 8-K | artv-20250128.htm |
| 2026-02-19 | 8-K | artv-20250128.htm |
| 2025-12-12 | 8-K | artv-20251210.htm |
| 2025-11-12 | 8-K | artv-20251112.htm |
| 2025-11-12 | 10-Q | artv-20250930.htm |
| 2025-08-13 | CORRESP | filename1.htm |